HEALTH INFORMATION TECHNOLOGY: A POWERFUL TOOL IN ATTACKING THE OPIOID CRISIS PAUL L. UHRIG CHIEF ADMINISTRATIVE, LEGAL & PRIVACY OFFICER

Similar documents
Telligen Quality Innovation Network Quality Improvement Organization

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Pennsylvania Prescription Drug Monitoring Program Trends,

Risk Classification Modeling to Combat Opioid Abuse

2017 PGIP Fact Sheet Electronic Prescribing of Controlled Substances (EPCS)

20% A Holistic Approach Built on Evidence OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR

The Opioid Epidemic and PerformRx s Approach to Address It: A Collaborative Model with PBM, Payor and Behavioral Health

Prescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD

Patient-Centered Measurement: Innovation Challenge Series

Although PDMPs are separately managed and maintained by each state or jurisdiction, the national network facilitates more uniformity among states.

The Challenge of Treating Pain

Economic Costs of Substance Abuse Dheeraj Raina, MD

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018

SUBHEAD GOES HERE. Addressing Tennessee s Opioid Crisis. Natalie A. Tate, PharmD Vice President, Pharmacy

New Guidelines for Prescribing Opioids

The Pharmacy Quality Alliance Optimizing Health by Advancing the Quality of Medication Use

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Vanila M Singh, MD MACM Chief Medical Officer Office of the Assistant Secretary for Health U.S. Department of Health and Human Services

Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention

Blue Cross of Idaho Addresses State s Opioid Issue

OPIOID EPIDEMIC AND WORKPLACE IMPLICATIONS

Morrison County Community-Based Care Coordination. Our Core Values Reverence Integrity Compassion Excellence

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

E-Prescribing, EPCS & PDMP: An Update

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices

FIGHTING ADDICTION AND IMPROVING BEHAVIORAL HEALTH

Association of State and Territorial Health Officials (ASTHO)

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic

National Viral Hepatitis Action Plan Priority Populations Approach

Michigan Legislative and Regulatory Pharmacy Initiatives Update

The Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health

TOWARD A REAL-TIME DRUG OVERDOSE MONITORING SYSTEM

2013 NATIONAL PROGRESS REPORT AND SAFE-Rx RANKINGS

BJA Harold Rogers PDMP National Meeting on Data Driven Multi-Disciplinary Approaches to Reducing Rx Abuse

Addressing the Opioid Epidemic in Tennessee

Managing Risks Associated with Doctor Shopping and Other Drug-Seeking Behaviors

Outline. Decreasing total opioid prescriptions Decreasing benzodiazepine and opioid co-prescription. Increasing community awareness of opioid risks

Quality Metrics & Immunizations

ASTHO President s Challenge 15 x 15: Reduce Prescription Drug

Strategies to Manage The Opioid Crisis

Michael M. Miller, MD, FASAM, FAPA

Community Engagement to Address the Opioid Crisis. Laura Palombi, PharmD, MPH, MAT, AE-C

Policy and Political Dynamics of the Opioid Addiction Crisis in the United States

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration

Prescription Opioid Overdose in Oregon: A public health perspective

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

National Dialogue for Healthcare Innovation s Opioid Crisis Solutions Summit: A Roadmap for Action

The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose

Opiate Use among Ohio Medicaid Recipients

Controlled Substance Prescribing Trends and Odds of Drug Overdose Death

PRIORITY 3 BEHAVIORAL HEALTH AIM: Create a sustainable system of behavioral health care. STATE HEALTH IMPROVEMENT PLAN

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

AMERICA S OPIOID EPIDEMIC AND ITS EFFECT ON THE NATION S COMMERCIALLY-INSURED POPULATION PUBLISHED JUNE 29, 2017

Wednesday, June 21, Dear Chairmen and Ranking Members:

Opioid Initiative Wave I PDMPs and Screening

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Public Attitudes on Regulatory Changes Affecting Pain Management

Managed Care Pushes for Safer Opioid Oversight

TITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT

Opioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016

July 6, Dear Governor Christie:

Update on the Opioid Crisis

What is the strategy?

Opioid epidemic and PEHP

STATEMENT FOR THE RECORD. Submitted to the. Senate Committee on Health, Education, Labor, & Pensions

The 23-person Behavioral Health and Substance Use Standing Committee reviewed nine measures. All nine measures were recommended for endorsement.

Treating pain without pills

Opioids drive continued increase in drug overdose deaths

Opioid Crisis: HHS Strategy and Advancing Pain Management

Confronting the Opioid Crisis at the State Level

Public Health Federal Funding Request to Address the Opioid Epidemic

NBPDP Drug Utilization Review Process Update

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Integrated Care Approach to Chronic Pain. David Charles, MD

Revive RVA: Regional Solutions to the Opioid Crisis

If you or someone you know needs help you can contact: Child Study Center 1210 Wolfe Street Little Rock, AR

Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County

Battling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic

Opioid Use: Current Challenges & Clinical Advancements

Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA

YOUTH OPIOID ABUSE PREVENTION TOOLKIT

OUR RESPONSE TO ADDRESS THE GROWING OPIOID EPIDEMIC

Prescription Drug Abuse:

Aetna s Initiative on the Opioid Epidemic

Hawaii Homeless Healthcare Hui H4

STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Evaluation of the N.C. Prescription

Putnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515

Update: How the CDC Guidelines Are Impacting Patient Care

Stark County Opiate Task Force

Touchpoints Prior to Opioid Overdose Death

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

The Opioid Addiction Crisis in the Northern Shenandoah Valley. A Community Response

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

Pocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Transcription:

HEALTH INFORMATION TECHNOLOGY: A POWERFUL TOOL IN ATTACKING THE OPIOID CRISIS PAUL L. UHRIG CHIEF ADMINISTRATIVE, LEGAL & PRIVACY OFFICER Copyright 2018 2017 by by Surescripts, LLC. All All rights reserved.

2 Copyright 2018 2017 by by Surescripts, LLC. All All rights reserved. 13.7

ELECTRONIC PRESCRIBING OF CONTROLLED SUBSTANCES (EPCS) Proven One efficient Technology workflow and for Risk all prescriptions Analysis Reduced fraud and abuse Secure electronic records Improved safety and patient care Permitted by DEA since 2010 & states by 2015 Annualized Cost Savings Potential of $700 Million Reduced pharmacy/prescriber phone callbacks Reduced need to store paper prescriptions Economic Impact Analysis of the Interim Final Electronic Prescription Rule DEA, U.S. Department of Justice, March 2010 3 Copyright Copyright 2018 2017 by Surescripts, by Surescripts, LLC. LLC. All rights All rights reserved. reserved.

73% OF MEDICATIONS ARE E-PRESCRIBED, BUT WE HAVE OPPORTUNITIES TO IMPROVE. NATIONAL +82% OF NON-CONTROLLED SUBSTANCES ARE E-PRESCRIBED. NATIONAL 19% OF CONTROLLED SUBSTANCES ARE E-PRESCRIBED. 4 Copyright 2018 2017 by by Surescripts, LLC. All All rights reserved.

EPCS TODAY 100.0% 90.0% E-Prescribing Enablement Status as of Feb 2018 97.1% 97.8% 95.5% 92.4% 94.4% 95.0% 91.0% 80.0% 70.0% 70.5% 66.0% 75.7% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 23.6% 14.6% 0.0% National Ohio New York % Active E-Prescribers % EPCS Enabled Prescribers % erx Enabled Pharmacies % EPCS Enabled Pharmacies 5 Copyright Copyright 2018 2017 by Surescripts, by Surescripts, LLC. LLC. All rights All rights reserved. reserved.

6 Copyright 2018 2017 by by Surescripts, LLC. All All rights reserved.

Copyright 2017 by Surescripts, LLC. All rights reserved.

Optimizing Patients' Health by Improving the Quality of Medication Use PQA Patient Safety Measures for Inappropriate Prescription Opioid Use Norris Turner, PharmD, PhD Vice President, Strategic Alliances and Measure Implementation Pharmacy Quality Alliance

Who is the Pharmacy Quality Alliance? Mission Statement: Improve the quality of medication management and use across health care settings with the goal of improving patients health through a collaborative process to develop and implement performance measures and recognize examples of exceptional pharmacy quality. Created in 2006 as a public-private partnership Multi-Stakeholder, Member-Based, Non-Profit Transparent & Consensus Based Process Nationwide Measure Developer 9 Pharmacy Quality Alliance

Rationale for PQA Opioid Prescribing Measures Nearly half of US opioid overdose deaths involve prescription opioids 1. CDC. Wide-ranging online data for epidemiologic research (WONDER); 2016. Available at http://wonder.cdc.gov. 2. Rudd RA, et al. MMWR Morb Mortal Wkly Rep. epub: 16 December 2016. DOI: http://dx.doi.org/10.15585/mmwr.mm6550e1 10 Pharmacy Quality Alliance

Rationale for Opioid Prescribing Measures (cont.) Nearly 1 of 4 people who receive long-term prescription opioids for noncancer pain struggles with addiction 1. SAMHSA. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits; 2013. Available at: http://www.samhsa.gov/data/2k13/dawn127/sr127-dawn-highlights.htm 2. Boscarino JA, et al., Addiction 2010;105:1776 82. http://dx.doi. org/10.1111/j.1360-0443.2010.03052.x Pharmacy Quality Alliance 11

PQA Opioids Measures 1. Use of Opioids at High Dosage in Persons without Cancer (NQF #2940) * 2. Use of Opioids from Multiple Providers in Persons without Cancer (NQF #2950) * 3. Use of Opioids at High Dosage and from Multiple Providers in Persons without Cancer (NQF #2951) * 4. Concurrent Use of Opioids and Benzodiazepines ** NQF = National Quality Forum * PQA-endorsed May 2015; NQF-endorsed March 2017 ** PQA-endorsed December 2016; seeking NQF endorsement in 2018 12 Pharmacy Quality Alliance

Multiple Providers Multiple prescribers or pharmacies associated with increased risk for potentially fatal overdose Risk increases with number of prescribers and pharmacies In West Virginia (2005-2007), 4 prescribers and 4 pharmacies in previous 6 months increased risk of drug-related death 3.6-fold 1 In Tennessee (2008-2011), 4 prescribers and 4 pharmacies increased risk of opioid-related overdose death 6.5- and 6.0-fold, respectively 2 1. Peirce GL, et al. Med Care. 2012;50(6):494-500. doi: 10.1097/MLR.0b013e31824ebd81. PubMed PMID: 22410408. 2. Gwira Baumblatt J et al. JAMA Intern Med 2014;174:796 801. PMID: 24589873. 13 Pharmacy Quality Alliance

Concurrent Use with Benzodiazepines Concurrent use of benzodiazepines with opioids increased overdose death risk 4-fold among US veterans (2004-09) 1 Concurrent use increased by nearly 80% (9% to 17%) among privately insured patients (2001-13) 2 Increased risk of ED visit or hospital admission for opioid overdose 2-fold Eliminating concurrent use could reduce population risk by 15% CDC guidelines: Avoid concurrent prescribing whenever possible 3 FDA added boxed warning to product labeling 4 1. Park et al. BMJ. 2015;350:h2698. doi: 10.1136/bmj.h2698. PMID: 26063215. 2. Sun et al. BMJ. 2017;356:j760. doi: 10.1136/bmj.j760. PMID: 28292769 3. CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016. Available at: https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm 4. FDA Drug Safety Communication. August 31, 2016. Available at: https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm518110.htm 14 Pharmacy Quality Alliance

Use of PQA Opioid Measures in Medicaid Medicaid Adult Core Measure Set High Dosage (#1) added to measure set in 2016 1 Concurrent Benzodiazepines (#4) conditionally supported (pending NQF endorsement) by the Measures Application Partnership for addition 2 NQF = National Quality Forum 1. Medicaid Adult Health Care Quality Measures. Available at: https://www.medicaid.gov/medicaid/quality-of-care/performancemeasurement/adult-core-set/index.html 2. Measures Application Partnership. Medicaid Adult Draft Report for Comment. August 8, 2017. Available at http://www.qualityforum.org/map_task_forces.aspx 15 Pharmacy Quality Alliance

Conclusion There is wide variation in opioid prescribing PQA opioid measures address high-risk opioid prescribing among persons without cancer Performance measures are one tool to address the US prescription opioid crisis Use of opioid measures in performance programs will be monitored for possible unintended consequences PQA will continue to evaluate the need for potential changes or additional measures 16 Pharmacy Quality Alliance